Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (DE:7AY1)
:7AY1
RESEARCH TOOLSreports
Total Valuation
Actinium Pharmaceuticals has a market cap or net worth of €50.09M. The enterprise value is -€6.80M.
Market Cap€50.09M
Enterprise Value-€6.80M
Share Statistics
Actinium Pharmaceuticals has 31,195,890 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,195,890
Owned by Insiders6.13%
Owned by Institutions2.05%
Financial Efficiency
Actinium Pharmaceuticals’s return on equity (ROE) is -1.17 and return on invested capital (ROIC) is -60.75%.
Return on Equity (ROE)-1.17
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-60.75%
Return on Capital Employed (ROCE)-0.61
Revenue Per Employee0.00
Profits Per Employee-1.23M
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Actinium Pharmaceuticals is -0.99. Actinium Pharmaceuticals’s PEG ratio is 0.08.
PE Ratio-0.99
PS Ratio0.00
PB Ratio2.22
Price to Fair Value1.16
Price to FCF-1.72
Price to Operating Cash Flow-1.72
PEG Ratio0.08
Income Statement
In the last 12 months, Actinium Pharmaceuticals had revenue of 0.00 and earned -38.24M in profits. Earnings per share was -1.27.
Revenue0.00
Gross Profit0.00
Operating Income-42.12M
Pretax Income-38.24M
Net Income-38.24M
EBITDA-37.43M
Earnings Per Share (EPS)-1.27
Cash Flow
In the last 12 months, operating cash flow was -33.27M and capital expenditures 0.00, giving a free cash flow of -33.27M billion.
Operating Cash Flow-33.27M
Free Cash Flow-33.27M
Free Cash Flow per Share-1.07
Dividends & Yields
Actinium Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.59
52-Week Price Change-80.85%
50-Day Moving Average1.31
200-Day Moving Average1.35
Relative Strength Index (RSI)54.87
Average Volume (3m)0.00
Important Dates
Actinium Pharmaceuticals upcoming earnings date is Nov 24, 2025, TBA Not Confirmed.
Last Earnings DateMar 14, 2025
Next Earnings DateNov 24, 2025
Ex-Dividend Date―
Financial Position
Actinium Pharmaceuticals as a current ratio of 9.14, with Debt / Equity ratio of 5.58%
Current Ratio9.14
Quick Ratio9.14
Debt to Market Cap0.02
Net Debt to EBITDA1.91
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Actinium Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Actinium Pharmaceuticals EV to EBITDA ratio is 0.89, with an EV/FCF ratio of 1.01.
EV to Sales0.00
EV to EBITDA0.89
EV to Free Cash Flow1.01
EV to Operating Cash Flow1.01
Balance Sheet
Actinium Pharmaceuticals has €65.33M in cash and marketable securities with $1.43M in debt, giving a net cash position of -€63.89M billion.
Cash & Marketable Securities€65.33M
Total Debt$1.43M
Net Cash-€63.89M
Net Cash Per Share-€2.05
Tangible Book Value Per Share€1.09
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Actinium Pharmaceuticals is €5.26, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€5.26
Price Target Upside265.56% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―